close Icon

Protektem babe blo yu: Preventing mother-to-child transmission of hepatitis B in Vanuatu

WHO recommends pregnant women with a high hepatitis B viral load receive tenofovir during pregnancy to prevent mother-to-child transmission, however there is limited access to viral load testing across Vanuatu and other Pacific Island Countries. This field trial compares the effectiveness of WHO-based guidelines to an alternative model of care, in which all hepatitis B-infected pregnant women receive tenofovir without requiring viral load testing, to prevent mother-to-child transmission of hepatitis B. 

  • To evaluate if the treat-all approach to managing hepatitis B-infected pregnant women leads to a reduction in hepatitis B among infants compared to a guideline-based care approach;

  • To evaluate and compare the acceptability, cost-effectiveness and safety of the treat-all and guideline-based care approaches to management of hepatitis B-infected pregnant women. 

2023 - 2025

A two-arm, parallel group, randomised trial with hepatitis B-infected pregnant women attending antenatal clinics in Port Vila, Vanuatu. Infants will be tested 6-12 months after birth. 

The treat-all approach is highly novel and will facilitate a major paradigm shift in prevention of mother-to-child transmission of hepatitis B in low and low-middle income countries including Pacific Island Countries. 

Pacific regional stakeholders will be consulted to determine the best strategy for regional roll-out of updated guidance. 

The impact of the intervention will be immediate in terms of averting hepatitis B infections in infants in Vanuatu. Scale-up of the intervention across the Pacific could avert hundreds of infections each year. 

Caroline Van Gemert

Caroline Van Gemert

Contact Caroline Van Gemert for more information about this project. 

EMAIL

Funding
Partners

  • Thrasher Research Fund

Partners +
Collaborators

  • Vanuatu Ministry of Health
  • Doherty Institute
  • VIDRL